The board of directors of Wai Yuen Tong Medicine Holdings Limited announced that the group is expected to record an increase in loss attributable to owners of the parent for the financial year ended 31 March 2018 by more than 30% as compared to the corresponding period in 2017. Such expected increase in loss is mainly attributable to, among other things, an one-off gain on disposal of a subsidiary recorded in 2017, an impairment loss in a property, an increase in overheads in the group's factories and a deemed dilution effect in an associate, as offsetting by the improvement effect on change in fair value of equity investments at fair value through profit and loss and change in fair value on investment properties for the year ended 31 March 2018.